Neuroimmunology in Clinical Practice - part 8 ppt

... GluR1 AGNA-1; ANNA-1,2,3; PCA-2; Ma2; CRMP-5; VGCC (P/Q>N-type) Amphiphysin CRMP-5; ANNA-1; 2, PCA-2 CRMP-5; recoverin CRMP-5; VGCC; amphiphysin; ganglionic AChR; VGKC; ANNA-1,2 ANNA-1; CRMP-5; ... blocked acetylcholine-induced increase in intracellular free calcium and inhibited 125 I-α-bungarotoxin bind- ing in cells expressing α7nAChR. The authors postulate that these antibodies...

Ngày tải lên: 10/08/2014, 00:20

... Brannagan III. p. ; cm. Includes bibliographical references and index. ISBN-13: 97 8- 1 -4 05 1-5 84 0-4 (hardback : alk. paper) ISBN-10: 1-4 05 1-5 84 0-9 (hardback : alk. paper) 1. Neuroimmunology. 2. Nervous ... glycoprotein with a single trans- membrane domain and is targeted to axons underly- ing paranodal regions of myelin sheaths in the CNS and PNS (Einheber et al., 19...

Ngày tải lên: 10/08/2014, 00:20

... whereas animals deficient in IL-12 alone develop severe dis- ease. Interleukin-23 induces IL-17 production by T cells. IL-17 is expressed in brain lesions and appears to be a regulator of CNS in ammation. T ... four clinical courses that are routinely used in practice (Lublin and Reingold, 1996). This empirical classification, in agreement with natural history studies, distinguishe...

Ngày tải lên: 10/08/2014, 00:20

... anti-CD40L/-CD154 (IDEC-131); anti-IL-12, anti-CD6; anti-CD3 (OKT3); anti-Vβ5.2/5.3 + T cells; anti-CD4; integrin inhibitors Lymphocyte-specific cytoplasmic protein – tyrosine kinase P56lck; zeta-associated protein ... 25-year-old male with secondary-progressive MS (a, b, c) showing homogeneously enhancing lesions (a) and from a 29-year-old female with relapsing-remitting MS (d, e, f ) showing...

Ngày tải lên: 10/08/2014, 00:20

... Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. 2001. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. ... 2006. Interferon-beta-1a slows down progression of brain atrophy in relapsing-remitting multiple sclerosis by reducing predominantly grey matter atrophy pro- gression. Mult Scle...

Ngày tải lên: 10/08/2014, 00:20

... T.K. 1 985 . Sequential electrodiagnostic abnormalities in acute in ammatory demyelinating polyradiculoneuro- pathy. Muscle Nerve, 8, 5 28 39 Arnason, B.G.W. 1 982 . Acute in ammatory demyelin- ating ... plasmapheresis in acute disseminated (post- infectious) encephalomyelitis. J Clin Apheresis, 7(4), 173 –9. Sugita, K., Suzuki, N., Shimizu, N. et al. 1993. Involvement of cytokines in...

Ngày tải lên: 10/08/2014, 00:20

... consistent benefit include indomethacin, somatostatin analogs, caffeine, ergot alkaloids, and nocturnal desmopressin. L-threo-3, 4-dihydroxyphenylserine is used in the rare but dis- tinctive entity, ... Brain, 81 , 157. Azulay, J.P., Blin, O., Pouget, J. et al. 1994. Intravenous immunoglobulin treatment in patients with motor- neuron syndromes associated with anti-Gm1 anti- bodies – A do...

Ngày tải lên: 10/08/2014, 00:20

... benefits. Cyclosporine A is an immunosupressant that blocks interleukin-2 activation of T-helper cells by inhibit- ing calcineurin. While a controlled, double-blind clinical trial has shown its effectiveness in ... screening for immunocytochemical staining for proteins known to be associated with muscular dystrophies is appropriate. The main finding in DM is perivascular B-cell-predominan...

Ngày tải lên: 10/08/2014, 00:20

... perivascular in ammation of the adventitia, and intimal prolifera- tion resulting in narrowing of arterial lumina. Later investigators (Kernohan and Woltman, 19 38) sum- marized the clinical and ... of IL-1, IL-6, and IL -8 ; expression of cell adhesion molecules (CAMs), namely integrins, selectins, and the immunoglobulin superfamily mole- cules (intercellular (ICAM-1), vascular (VCAM-1...

Ngày tải lên: 10/08/2014, 00:20

... syndrome 49, 185 8, 2 28 cerebrospinal fluid 186 –7 clinical presentation 185 –6 diagnosis 185 imaging 186 pathology 187 treatment 187 beta interferon adverse effects 65 in MS 64–5 blood–brain barrier ... disease 83 –7, 106, 107 cerebrospinal fluid 84 clinical phenotype 83 –4 diagnostic criteria 86 genetics 85 MRI 84 , 84 NMO-IgG biomarker 85 –6 pathology 84 –5 treatment...

Ngày tải lên: 10/08/2014, 00:20